Non-Malignant Haematology (NMH)
The remit of the Non-Malignant Haematology (NMH) Specialty Group is to support a national portfolio of structured research studies in the field of NMH. The main purposes of the Specialty Group are to ensure that clinical research studies in NMH are delivered to target by developing and supporting a research infrastructure within the specialty which promotes engagement within haematology and provides the local support necessary to undertake high quality research studies within the NHS. The NMH Specialty Group’s portfolio includes: Haemoglobinopathy, Haemostasis and thrombosis, Blood transfusion, Platelet disorders and Stem cell research
There is overlap between the NMH Specialty Group and many other Specialty Groups and NIHR Topic Specific Research Networks.
In general, the NMH Specialty Group will take the lead on research studies which are led by haematologists.
Specialty Group Lead: Dr David Rees Biography
David Rees is a Senior Lecturer and Honorary Consultant in Paediatric Haematology at King’s College Hospital NHS Foundation Trust. He has research and clinical interests in paediatric sickle cell disease, and other inherited red cell abnormalities, including porphyrias, thalassaemia and enzymopathies.
He trained at Cambridge University and St Thomas’ Hospital Medical School and has previously worked in London, Oxford and Sheffield. He spent six years in the Weatherall Institute of Molecular Medicine in Oxford researching thalassaemia. He is involved in the care of more than 500 children with sickle cell disease and thalassaemia in southern England and active in clinical and laboratory-based research on haemoglobinopathies. He is a medical adviser to the Sickle Cell Society in the UK.
Visit the National Non-Malignant Haematology (NMH) Specialty Group for further information.